Towards Healthcare
AI in Biotechnology Market to Rise at 19.04% CAGR till 2034

AI in Biotechnology Market Dynamics Driving Global Adoption

According to market projections, the AI in biotechnology sector is expected to grow from USD 3.27 billion in 2024 to USD 18.76 billion by 2034, reflecting a CAGR of 19.04%. The market is growing globally as AI accelerates drug discovery, genomics research, and personalized medicine. North America dominates the market due to advanced biotech infrastructure, high R&D investments, and widespread AI adoption in healthcare and pharmaceuticals.

Content

  • Last Updated: 14 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The AI in biotechnology market is valued at USD 3.89 billion in 2025 and is on track to reach USD 18.76 billion by 2034, witnessing a steady CAGR of 19.04% during the forecast span.

North America is currently leading the AI in biotechnology market share 50% due to its well-established pharmaceutical and biotech industry, advanced computational infrastructure, and high adoption of AI technologies.

The AI in biotechnology market includes 5 segments by primary application/use case, by core AI technology, by commercial model, by end user/buyer type by region.

AI predicts drug-target interactions, designs new molecules, analyzes clinical trial data, and helps in lead identification to shorten development timelines.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration. \n\n
Any Questions